Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Consequences in the blink of an eye
  • Acknowledgments
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Commentary Free access | 10.1172/JCI70226

Chronic THC intake modifies fundamental cerebellar functions

Nephi Stella

Department of Pharmacology, University of Washington, Seattle, Washington, USA.

Address correspondence to: Nephi Stella, Department of Pharmacology, joint with Psychiatry and Behavioral Sciences, 1959 N.E. Pacific St., BB-1538, HSC, Box 357280, Seattle, Washington 98195-7280, USA. Phone: 206.221.5220; E-mail: nstella@uw.edu.

Find articles by Stella, N. in: PubMed | Google Scholar

Published July 1, 2013 - More info

Published in Volume 123, Issue 8 on August 1, 2013
J Clin Invest. 2013;123(8):3208–3210. https://doi.org/10.1172/JCI70226.
© 2013 The American Society for Clinical Investigation
Published July 1, 2013 - Version history
View PDF

Related article:

Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure
Laura Cutando, … , Rafael Maldonado, Andrés Ozaita
Laura Cutando, … , Rafael Maldonado, Andrés Ozaita
Research Article

Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure

  • Text
  • PDF
Abstract

Chronic cannabis exposure can lead to cerebellar dysfunction in humans, but the neurobiological mechanisms involved remain incompletely understood. Here, we found that in mice, subchronic administration of the psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), activated cerebellar microglia and increased the expression of neuroinflammatory markers, including IL-1β. This neuroinflammatory phenotype correlated with deficits in cerebellar conditioned learning and fine motor coordination. The neuroinflammatory phenotype was readily detectable in the cerebellum of mice with global loss of the CB1 cannabinoid receptor (CB1R, Cb1–/– mice) and in mice lacking CB1R in the cerebellar parallel fibers, suggesting that CB1R downregulation in the cerebellar molecular layer plays a key role in THC-induced cerebellar deficits. Expression of CB2 cannabinoid receptor (CB2R) and Il1b mRNA was increased under neuroinflammatory conditions in activated CD11b-positive microglial cells. Furthermore, administration of the immunosuppressant minocycline or an inhibitor of IL-1β receptor signaling prevented the deficits in cerebellar function in Cb1–/– and THC-withdrawn mice. Our results suggest that cerebellar microglial activation plays a crucial role in the cerebellar deficits induced by repeated cannabis exposure.

Authors

Laura Cutando, Arnau Busquets-Garcia, Emma Puighermanal, Maria Gomis-González, José María Delgado-García, Agnès Gruart, Rafael Maldonado, Andrés Ozaita

×

Abstract

Delta9-tetrahydrocannabinol (THC), the principal bioactive component in the Cannabis plant, is truly a captivating drug. Acute and chronic THC intake produces a spectrum of biological effects ranging from transient psychotropic effects to prolonged medicinal benefits, many of which have been fostered for centuries by our society. In the July 2013 issue of the JCI, Cutando et al. combined mouse genetics with classic mouse behavioral analysis to deepen our understanding of the physiological consequence of subchronic THC intake on eyeblink reflexes, a fundamental neuronal adaptive response, revealing that this regimen leads to downregulation of the cannabinoid CB1 receptor (referred to as CB1 in the Cutando et al. article) in cerebellar stress fibers and the activation of microglia, raising provocative new questions about the safety profile of regimented THC intake.

Consequences in the blink of an eye

Our detailed understanding of the molecular mechanism of action of THC on neuronal activity began 20 years ago with the molecular identification of the gene encoding for CB1 receptors, which mediate the psychoactive effects produced by this compound (1). CB1 receptors represent one of the most abundant G protein–coupled receptors expressed in the brain, although the expression level and coupling mechanism vary according to neuron type (2). Activation of CB1 receptors by endogenous cannabinoid ligands, the endocannabinoids (eCBs), modulates neuronal activity at 4 overarching levels: by guiding neuronal patterning and connectivity during brain development (3); by modulating neurotransmitter release probability (4); by mediating short-term and long-term synaptic plasticity and shaping neuronal network connectivity (5, 6); and by controlling the expression of prosurvival proteins that promote neuronal endurance in response to brain injuries and pathologies (7). Unlike eCBs, THC activates CB1 receptors with its own pharmacodynamic profile and thus may impinge upon neuronal activity at these 4 levels (8).

The effect of THC on higher sensory, intentional, and memory processes has been intensely studied, but more recently, a major research focus has been on how THC affects neuronal activity at the systems level, revealing the breadth of THC’s impact on behavior. In the current study, Cutando et al. (9) investigated the effect of subchronic THC exposure on cerebellar function. The cerebellum represents a key relay structure involved in the fine tuning of motor coordination, the implementation of associative learning, and the processing of temporal operations. Cutando et al. (9) found that subchronic THC exposure led to the impairment of motor coordination and eyeblink reflex conditioning in mice, both of which are archetypal examples of cerebellar-associated learning. Eyeblink conditioning was achieved by presenting an auditory stimulus (i.e., conditioned stimulus [CS]) to the mice, followed by an eyeblink-eliciting unconditioned stimulus (US) elicited by a mild air puff. Following repeated CS-US trials, a conditioned response (CR) that preceded US onset was measured. In humans, repeated THC intake has previously been shown to markedly reduce the incidence and timing of this neuronal adaptive response (10). Here, Cutando et al. (9) found in mice that the THC-induced behavioral impairment was related to the rapid and strong downregulation of CB1 receptors.

How lighting up ignites inflammation What would be the significance of losing eCB signaling through CB1 receptors, and what brain areas would be affected by this change? Loss of presynaptic CB1 receptor signaling and control of neurotransmitter release increases the probability of glutamate release and promotes excitotoxicity (7, 11). Microglial cells, the macrophages of the brain, act as sentinels for neuronal dysfunction and injury, constantly surveying the parenchyma by extending and retracting their fine processes and sampling for the presence of cell damage signals and pathogens (12). Once microglia encounter such a signal of injury or pathogen, they undergo a rapid change in phenotype that empowers them with immune functions tailored to attempt to reduce and repair any tissue damage. Accordingly, one can monitor brain tissue for microglial cell activation and easily locate the damaged areas. In this study, the authors found that subchronic THC intake leads to microglial activation specifically in the cerebellum. To further define the cellular components mediating this neuroinflammatory response, Cutando et al. developed a new mouse model that lacks the CB1 receptor selectively in cerebellar parallel fibers (Cb1a6– mice) and found selective activation of microglia in the cerebellum of these mice, demonstrating that loss of CB1 signaling due to receptor downregulation or genetic deletion induces a neuroinflammatory response (ref. 9 and Figure 1). This seemingly simple result points to an important new concept: it suggests that one function of CB1 receptors expressed by cerebellar stress fibers is to maintain homeostasis within the cerebellum and that disruption of this homoeostasis triggers microglial cell activation and neuroinflammation. Remarkably, the authors found no direct evidence of neuronal damage, suggesting that the impaired neuronal adaptation measured by the eyeblink reflex was not due to actual neuronal loss but rather to changes in neurotransmitter release from the stress fibers onto Purkinje cells.

In mice, subchronic treatment with THC leads to the downregulation of presyFigure 1

In mice, subchronic treatment with THC leads to the downregulation of presynaptic cannabinoid CB1 receptors expressed by parallel fibers that project onto Purkinje cells. Cutando et al. (9) show that the loss of CB1 receptors, either due to TCH-induced downregulation or genetic deletion, triggers a neuroinflammatory response typified by changes in microglial cell morphology and CB2 receptor expression. This adaptive response underlies THC-induced deficits in cerebellar-associated learning functions.

Connecting impaired CB1 signaling to neuroinflammation While CB1 receptor downregulation in response to repeated THC intake typically develops within hours, the ensuing neuroinflammatory response developed after 5 days in this experimental paradigm (9). To understand this delay, one needs to consider that alteration of the microglial phenotype is dynamic and complex and involves sequential changes in the expression of specific proteins, many of which have established roles in immune response. To start, while changes in microglial morphology unmistakably indicate cell activation, the actual differences in microglial cell morphologies (e.g., bushy versus amoeboid morphologies) remain difficult to interpret, as these do not necessarily correlate with particular immune phenotypes adopted by these cells. Conversely, quantifying changes in the expression of select proteins that have known biological roles in microglia may provide a sharper image of the microglial cell phenotype and the type of neuroinflammatory response that has developed in the parenchyma. In this study, the authors demonstrate an increased expression of 2 proteins with established immune functions in microglia: the cannabinoid CB2 receptor (referred to as CB2 in the Cutando et al. article) and the immune modulator IL-1β (9). Upregulation of CB2 receptors in microglia may indicate that these cells are now able to sense increases in local eCB levels resulting from neuronal overactivation and damage (13); activation of CB2 receptors in microglia directs their migration toward damaged cells and reduces their ability to release proinflammatory mediators, while promoting the release of repair mediators. Conversely, upregulation of IL-1β in microglia is typically associated with a proinflammatory phenotype and the propagation of the neuroinflammatory response (14). Thus, subchronic THC intake leads to the retraction of cell processes by microglia in order to adopt a bush morphology and leads to a concomitant upregulation of the proinflammatory cytokine IL-1β and antiinflammatory CB2 receptors. While further studies are required to better understand how this particular neuroinflammatory profile leads to behavior impairment, the authors show that blocking IL-1 signaling ameliorates THC-mediated impairment of the eyeblink reflex (9).

High times for THC The study by Cutando et al. (9) in the July 2013 issue of the JCI outlines the molecular and cellular consequences of subchronic THC intake in a fundamental neuronal adaptive response involving the cerebellum. While our society is progressively accepting the legalization and commercialization of products containing THC for recreational and medicinal use, a portion of the population remains concerned about the health consequences associated with chronic or subchronic THC exposure. To reassure them, one might point to both the low incidence of side effects measured under strict clinical trial conditions when testing the therapeutic value of THC (15). However, the cerebellum is involved in fine tuning motor coordination, implementing associative learning, and processing temporal operations, and such behaviors are typically not measured under clinical trial settings and are rarely commented on by THC users. The study by Cutando et al. (9) raises fascinating new questions about the effect of subchronic THC intake on the cerebellum’s ability to fine tune higher cognitive functions, including its ability to produce rhythmic neuronal activity, thought to be linked to the ability to estimate time. Studies pioneered by Valentino Braitenberg have suggested that the anatomical organization of Purkinje neurons and their precise and regular innervation and excitation by stress fiber synapses originating from granule cells are likely to encode precisely timed behaviors (16). Altered time perception is often reported by individuals with THC intoxication and could be linked to temporal disintegration that is linked to an increase in internal clock speed (17, 18). We now have the genetic and pharmacological tools to explore one of the most fascinating and mysterious biological questions, and one that is largely unanswered: how do we perceive time and how is this modified by drug intake?

These are exciting times for cannabinoid research. By combining mouse genetics and classic mouse behavioral analysis, Cutando et al. (9) have helped to map the neuronal types and pathways controlled by CB1 receptors, shedding light on THC’s bioactivity on many fundamental biological functions and discovering how it regulates specific pathophysiological processes.

Acknowledgments

Address correspondence to: Nephi Stella, Department of Pharmacology, joint with Psychiatry and Behavioral Sciences, 1959 N.E. Pacific St., BB-1538, HSC, Box 357280, Seattle, Washington 98195-7280, USA. Phone: 206.221.5220; E-mail: nstella@uw.edu.

Footnotes

Conflict of interest: The author has declared that no conflict of interest exists.

Reference information: J Clin Invest. 2013;123(8):3208–3210. doi:10.1172/JCI70226.

See the related article beginning on page 2816.

References
  1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–564.
    View this article via: PubMed CrossRef Google Scholar
  2. Steindel F, et al. Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus. J Neurochem. 2013;124(6):795–807.
    View this article via: PubMed CrossRef Google Scholar
  3. Berghuis P, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316(5828):1212–1216.
    View this article via: PubMed CrossRef Google Scholar
  4. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14(9):923–930.
    View this article via: PubMed CrossRef Google Scholar
  5. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models. Nature. 2007;445(7128):643–647.
    View this article via: PubMed CrossRef Google Scholar
  6. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G. Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci. 2006;9(12):1526–1533.
    View this article via: PubMed CrossRef Google Scholar
  7. Marsicano G, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302(5642):84–88.
    View this article via: PubMed CrossRef Google Scholar
  8. Straiker A, Mackie K. Cannabinoids, electrophysiology, and retrograde messengers: challenges for the next 5 years. AAPS J. 2006;8(2):E272–E276.
    View this article via: PubMed Google Scholar
  9. Cutando L, et al. Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure. J Clin Invest. 2013;123(7):2816–2831.
    View this article via: JCI CrossRef Google Scholar
  10. Skosnik PD, Edwards CR, O’Donnell BF, Steffen A, Steinmetz JE, Hetrick WP. Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning. Neuropsychopharmacology. 2008;33(6):1432–1440.
    View this article via: PubMed CrossRef Google Scholar
  11. Tonini R, et al. ERK-dependent modulation of cerebellar synaptic plasticity after chronic Delta9-tetrahydrocannabinol exposure. J Neurosci. 2006;26(21):5810–5818.
    View this article via: PubMed CrossRef Google Scholar
  12. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58(9):1017–1030.
    View this article via: PubMed CrossRef Google Scholar
  13. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology. 2009;1:244–253.
    View this article via: PubMed Google Scholar
  14. Molina-Holgado F, et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci. 2003;23(16):6470–6474.
    View this article via: PubMed Google Scholar
  15. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci. 1976;282:221–239.
    View this article via: PubMed CrossRef Google Scholar
  16. Braitenberg V, Heck D, Sultan F. The detection and generation of sequences as a key to cerebellar function: experiments and theory. Behav Brain Sci. 1997;20(2):229–245.
    View this article via: PubMed Google Scholar
  17. Mathew RJ, Wilson WH, Turkington TG, Coleman RE. Cerebellar activity and disturbed time sense after THC. Brain Res. 1998;797(2):183–189.
    View this article via: PubMed CrossRef Google Scholar
  18. O’Leary DS, et al. Marijuana alters the human cerebellar clock. Neuroreport. 2003;14(8):1145–1151.
    View this article via: PubMed CrossRef Google Scholar
Version history
  • Version 1 (July 1, 2013): No description
  • Version 2 (August 1, 2013): No description
  • Version 3 (August 1, 2013): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Consequences in the blink of an eye
  • Acknowledgments
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts